Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Novartis India has reported total income of Rs. 91.59 crores during the period ended March 31, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
Subscribe To Our Newsletter & Stay Updated
